Program
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
*-Short talk from proffered abstract
wednesday, september 27, 2023
thursday, september 28, 2023
- Plenary Session 1: Epidemiology and Early Detection in Honor of Dr. Gloria Petersen
- Plenary Session 2: Diversity and Disparities
- Plenary Session 3: Clinical Updates
friDAY, september 29, 2023
- Plenary Session 4: Systems Biology, Big Data, and Metastasis
- Plenary Session 5: Metabolic Perturbations
- Plenary Session 6: RAS, Oncogene Addiction, and Other Targeted Therapies
SaturDAY, september 30, 2023
- Plenary Session 7: Model Systems and Bioengineering
- Plenary Session 8: Therapeutic Opportunities in Tumor Stromal and Immune Microenvironment
Wednesday, September 27, 2023
WELCOME AND KEYNOTE Lectures
5:45-7:30 P.M.
Welcome from Cochairs
Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina
Welcome from Lustgarten Foundation, Lead Supporter
Andrew Rakeman, Lustgarten Foundation, Woodbury, New York
Rising Star Keynote
“RNA switches” in pancreatic cancer: Expression, splicing and RNA-based therapeutics
Luisa F. Escobar-Hoyos, Yale School of Medicine, New Haven, Connecticut
Lightning Talk Session
Xianghui Zou, Zucker School of Medicine, Manhasset, New York
Yukihito Kuroda, University of Tsukuba, Tsukuba, Japan
Sabine Naudin, International Agency for Research on Cancer, Lyon, France
Deepti Mathur, Memorial Sloan Kettering Cancer Center, New York, New York
Mehrdad Zarei, Case Western Reserve University, Cleveland, Ohio
Kevin MacPherson, Oregon Health & Science University, Portland, Oregon
Opening Keynote
Title to be announced
Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York
Poster session A/OPENING RECEPTION
7:30-9 P.M.
Thursday, September 28, 2023
BREAKFAST
7-8 A.M.
BREAKFAST roundtables
7-8 A.M.
Limited to 100 participants; attendance to the Career Roundtables will be on a first-come, first-served basis and with no pre-registration required. Participants will be asked to rotate tables every 20 minutes, providing the opportunity to network and interact with a diverse cadre of expert mentors.
| Table Topic | Table Topic |
| Conducting Translational Research: How to Get Started Kathleen McAndrews, The University of Texas MD Anderson Cancer Center, Houston, Texas | Collaborating with Industry Erkut Borazanci, Honor Health Research Institute, Scottsdale, Arizona |
| Choosing a Career Path: Academia vs Industry (1 of 2) Leny Gocheva, Break Through Cancer, Cambridge, Massachusetts Paul Kurywchak, Skipper BioMed LLC, Houston, Texas | Starting Your Lab Jason R. Pitarresi, University of Massachusetts Medical School, Worcester, Massachusetts |
| Choosing a Career Path: Academia vs Industry (2 of 2) Laura Wood, Johns Hopkins, Baltimore, Maryland Harmeet Dhani, Biological Dynamics, San Diego, California | Getting Tenure Kenneth Olive, Herbert Irving Comprehensive Cancer Center, New York, New York Rushika Perera, University of California San Francisco, San Francisco, California |
| How to Get a Paper Published Christine Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York Ben Stanger, University of Pennsylvania, Philadelphia, Pennsylvania Harmony Turk, Executive Editor Cancer Research | Balancing Clinical and Research Life Jashodeep Datta, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida Cristina Ferrone, Cedars-Sinai Medical Center, Los Angeles, California |
| How to Write a Grant (1 of 2) Peter Allen, Duke University School of Medicine, Durham, North Carolina Mandar Mazumdar, Yale School of Medicine, New Haven, Connecticut | Entrepreneurship David Ting, Massachusetts General Hospital, Boston, Massachusetts Manuel Hidalgo, Weil Cornell Medicine,Nnew York, New York |
| How to Write a Grant (2 of 2) Marina Pasca di Magliano, University of Michigan Medical School, Ann Arbor, Michigan Kirsten Bryant, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina | Encouraging Diversity in Your Team Zobeida Cruz-Montserrate, The Ohio State University, Columbus, Ohio |
PLENARY SESSION 1: Epidemiology and Early Detection (In Honor of Dr. Gloria PetersEn)
Session Chair: Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, Texas
8:15-10 A.M.
Genetic epidemiology of pancreatic cancer: Past, present and future
Alison Klein, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Implementation of a real-time AI-guided navigation service for pancreas cancer*
Kristen M. John, Zucker School of Medicine, New Hyde Park, New York
Molecular detection of pancreatic cancer using methylated DNA markers
Shounak Majumder, Mayo Clinic, Rochester, Minnesota
Deep proteomics identifies novel biomarker candidates and molecular pathways of pancreatic cancer-related diabetes*
Lucy Oldfield, University of Liverpool, Liverpool, United Kingdom
Emerging trends and risk factors for pancreatic cancer in multiethnic populations
V. Wendy Setiawan, USC Norris Comprehensive Cancer Center, Los Angeles, California
BREAK
10-10:30 A.M.
PLENARY SESSION 2: Diversity and Disparities
Session Chair: Nicolette J. Rodriguez, Brigham and Women’s hospital/dana-farber cancer institute, Boston, Massachusetts
10:30 A.M.-12:15 P.M.
Advancing equity in access to PDAC cancer genetics and prevention
Nicolette J. Rodriguez
Addressing disparities in the Native American population in Oregon: The development of multi-disciplinary frameworks to study pancreatic ductal adenocarcinoma in Native American communities*
Jared Delaney, Oregon Health & Science University, Portland, Oregon
Diversity and disparity in pancreatic cancer care
Jose Trevino, VCU Massey Cancer Center, Richmond, Virginia
Who does the cutting-edge leave behind? – Inequities at the frontiers of pancreas cancer care
Ugwuji N. Maduekwe, Medical College of Wisconsin, Milwaukee, Wisconsin
LUNCH
12:15-2:15 P.M.
PLENARY SESSION 3: Clinical Updates
Session Chair: Talia Golan, Sheba Medical Center, Ramat Gan, Israel
2:15-4:40 P.M.
Spectrum of response to platinum and PARP inhibitors in HR-deficient pancreatic cancer
Talia Golan
Therapeutic development platform for pancreatic cancer in the UK national health service: Lessons learned and initial results from Precision-Panc*
David K. Chang, University of Glasgow, Glasgow, United Kingdom
CheMo4METPANC: Combination Chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in METastatic treatment-naïve PANCreatic adenocarcinoma*
Gulam A. Manji, Columbia University Irving Medical Center/New York Presbyterian, New York, New York
Pancreatic cancer clinical updates
Cristina R. Ferrone, Cedars-Sinai, Los Angeles, California
CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Interim efficacy results of the OPTIMIZE-1 phase 1b/2 study*
Teresa Macarulla, Vall d’Hebrón University Hospital, Barcelona, Spain
Clinical updates: Refining the role of radiation in the treatment of pancreas cancer
Manisha Palta, Duke Cancer Center, Durham, North Carolina
Lightning Presentations
Brandon Huffman, Dana-Farber Cancer Institute, Boston, Massachusetts
Deepika Bhullar, Sanford Burnham Prebys Medical Discovery Institute, San Diego, California
Amanda Decker-Farrell, Columbia University Irving Medical Center, New York, New York
Megan Hoffman, Dana-Farber Cancer Institute, Boston, Massachusetts
Keilah Garcia Netto, University of New South Wales, Sydney, Australia
POSTER SESSION B/RECEPTION
4:40-6:40 P.M.
Friday, September 29, 2023
BREAKFAST
7-8 A.M.
PLENARY SESSION 4: Systems Biology, Big Data, and Metastasis
Session chair: Steven Gallinger, Ontario Institute for Cancer Research, Toronto, ONtario, Canada
8-10 A.M.
Developmental and MAPK-responsive programs drive distinct malignant subtypes and genetic dependencies in pancreatic cancer
Andrea Califano, Columbia University, New York, New York
Unravelling the epigenetic landscape of pancreatic cancer: The role of cancer-associated fibroblasts*
Catarina Pelicano, CRUK University of Cambridge, Cambridge, United Kingdom
Forecasting pancreatic carcinogenesis through spatial multi-omics
Elana J. Fertig, Johns Hopkins University, Baltimore, Maryland
Spatial mapping of transcriptomic and lineage diversity in metastatic pancreatic cancer*
Jimin Min, UT MD Anderson Cancer Center, Houston, Texas
What the surgeon has learned from pancreas cancer genomics, and vice versa
Steven Gallinger
BREAK
10-10:30 A.M.
PLENARY SESSION 5: Metabolic Perturbations
Session Chair: Rushika Perera, University of California San Francisco, San Francisco, California
10:30 A.M.-12:30 P.M.
Feeding the flames of pancreatic cancer
Mandar Muzumdar, Yale School of Medicine, New Haven, Connecticut
Pancreatic cancer cachexia is mediated by tumor-derived PTHrP*
Jason R. Pitarresi, University of Massachusetts Medical School, Worcester, Massachusetts
Identifying and disabling the metabolic engines that fuel pancreatic cancer
Rushika Perera
Uridine-to-ribose axis supports glucose-restricted pancreatic cancer*
Zeribe C. Nwosu, University of Michigan, Ann Arbor, Michigan
Molecular mechanisms of obesity-associated pancreatic ductal adenocarcinoma
Zobeida Cruz-Monserrate, The Ohio State University, Columbus, Ohio
LUNCH ON OWN
12:30-2:30 P.M.
career roundtables
1-2 P.M.
Limited to 100 participants; attendance to the Career Roundtables will be on a first-come, first-served basis and with no pre-registration required. Participants will be asked to rotate tables every 20 minutes, providing the opportunity to network and interact with a diverse cadre of expert mentors.
| Table Topic | Table Topic |
| Conducting Translational Research: How to Get Started Steven Gallinger, Ontario Institute for Cancer Research, Toronto, Ontario, Canada | Collaborating with Industry Julian Adams, Stand Up To Cancer, Los Angeles, California Timothy Donahue, UCLA David Geffen School of Medicine, Los Angeles, California |
| Choosing a Career Path: Academia vs Industry (1 of 2) Gargi Basu, EXACT Sciences Corporation, Madison, Wisconsin Arnav Mehta, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts | Starting Your Lab Yang Chen, University of Texas MD Anderson Cancer Center, Houston, Texas William Freed-Pastor, Dana-Farber Cancer Institute, Boston, Massachusetts |
| Choosing a Career Path: Academia vs Industry (2 of 2) John Morris, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina | Getting Tenure Ingunn Stromnes, University of Minnesota, Minneapolis, Minnesota Eric Collisson, University of California San Francisco, San Francisco, California |
| How to Get a Paper Published Direna Alonso Curbelo, Institute for Research in Biomedicine – IRB Barcelona, Barcelona, Spain Anirban Maitra, University of Texas MD Anderson Cancer Center, Houston, Texas Avital (Tali) Lev, Senior Editor Cancer Discovery | Balancing Clinical and Research Life Filip Bednar, University of Michigan, Ann Arbor, Michigan Eileen O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York |
| How to Write a Grant (1 of 2) Rosalie Sears, Oregon Health & Science University, Portland, Oregon Howard Crawford, Henry Ford Health System, Detroit, Michigan | Entrepreneurship Jen Jen Yeh, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina |
| How to Write a Grant (2 of 2) Andy Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts John Brody, Oregon Health & Science University, Portland, Oregon | Encouraging Diversity in Your Team Brittany Allen-Petersen, Purdue University, West Lafayette, Indiana Debora Vendramini Costa, Henry Ford Health System, Detroit, Michigan |
PLENARY SESSION 6: RAS, Oncogene addiction, and Other Targeted Therapies
Session Chair: Rosalie C. Sears, Oregon Health & Science University, Portland, Oregon
2:30-4:40 P.M.
KRAS inhibition and the TME: Two for the price of one
Ben Z. Stanger, University of Pennsylvania, Philadelphia, Pennsylvania
KRAS mutant-specific interactions reveal mechanisms in pancreatic cancer tumorigenesis and metabolic function*
G. Aaron Hobbs, Medical University of South Carolina, Charleston, South Carolina
Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer
Ronald A. DePinho, UT MD Anderson Cancer Center, Houston, Texas
Targeting CDK7/9 in basal pancreatic cancer*
Sita Kugel, Fred Hutch Cancer Center, Seattle, Washington
MYC’s role in liver metastatic poor outcome pancreatic ductal adenocarcinoma
Rosalie C. Sears
Lightning Presentations
Peter Yu, NYU Grossman School of Medicine, New York, New York
Kyle McAndrews, University of Nebraska Medical Center, Omaha, Nebraska
Johann Gout, Institute for Molecular Oncology and Stem Cell Biology, Ulm, Germany
Ifeanyichukwu Ogobuiro, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida
POSTER SESSION c/ RECEPTION
4:40-6:40 P.M.
Saturday, september 30, 2023
CONTINENTAL BREAKFAST
7-8 A.M.
PLENARY SESSION 7: Model Systems
Session Chair: Jonathan R. Brody, OHSU Knight Cancer Institute, Portland, Oregon
8-10 A.M.
Addressing the hallmarks of pancreatic cancer
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
Single-cell mapping reveals a common origin for diverse subtypes of pancreatic cancer*
Nirakar Rajbhandari, University of California San Diego, La Jolla, California
Understanding KRAS cancer initiation and progression
Lukas E. Dow, Weill Cornell Medicine, New York, New York
Ex vivo models of pancreatic cancer that recapitulate the metabolic tumor microenvironment identify glycine as a chemoresistance-inducing oncometabolite*
Alexander Muir, University of Chicago, Chicago, Illinois
PDAC’s response to a stressful environment reveals targets and resistance mechanisms
Jonathan R. Brody
BREAK
10-10:15 A.M.
PLENARY SESSION 8: Therapeutic opportunities in tumor stromal and immune microenvironments
Session Chair: Ingunn M. Stromnes, University of Minnesota, Minneapolis, Minnesota
10:15 A.M.-12:15 P.M.
Pancreatic cancer – exceptional survivors to RNA vaccines
Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York
Adenosine inhibits STING driven anti-tumor immunity in pancreatic cancer*
Alykhan Premji, University of California Los Angeles, Los Angeles, California
Tumor Microbes driving therapies responses
Florencia McAllister, UT MD Anderson Cancer Center, Houston, Texas
Neutrophil-intrinsic tumor necrosis factor (TNF) is a novel driver of T-cell and cancer-associated fibroblast (CAF) dysfunction in pancreatic cancer*
Anna Bianchi, University of Miami Miller School of Medicine, Miami, Florida
Elucidating mechanisms governing immunotherapy response in pancreatic cancer
Ingunn M. Stromnes
CLOSING REMARKS
12:15 P.M.
Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York
Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, Texas
Rosalie C. Sears, Oregon Health & Science University, Portland, Oregon
Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina